ArticleApplied biochemistry and biotechnology2026
Integrated Multi-Omics Analysis of Gut Microbiota-Associated Metabolites and Related Host Molecular Signatures in Cervical Squamous Cell Carcinoma.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) is a common female malignancy. Gut microbiota and metabolites are critical regulators of tumor immunity and therapy, but their roles in CESC remain unclear. This study integrated TCGA and GEO datasets with gut microbiota information to construct a protein-protein interaction network. These targets were prioritized using machine learning, SHAP interpretation, and Mendelian randomization analysis. Immune-related pathways were explored using single-cell and spatial transcriptomic analyses. Molecular docking and molecular dynamics simulations were performed to evaluate potential interactions between key metabolites and their targets. A total of 136 gut microbiota-related DEGs were identified, which may be associated with intercellular immune interactions. KDR was selected as a core target and may exert protective effects. Single-cell and spatial transcriptomic analyses suggested that specific metabolites may be associated with changes in the tumor microenvironment potentially involving the MIF signaling pathway. Network analysis of microbes, metabolites, and targets suggested that metabolites such as 5-(3,4-dihydroxyphenyl) pentanoic acid may serve as key mediators linking gut microbiota and KDR signaling. Additionally, eight non-toxic metabolites with favorable drug-likeness were identified, molecular docking and molecular dynamics simulation demonstrated stable binding to KDR with potential bioactivity, providing a theoretical basis for developing microbiota-related therapeutic strategies. The gut microbiota and its metabolites may be associated with the immune microenvironment and tumor progression in CESC, potentially involving the MIF signaling axis. This study provides a computational framework and preliminary evidence supporting microbiota-related hypotheses, and may inform future experimental investigations and therapeutic strategy development.
Indexed as
Identifiers
42640410What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.